Insights into protein kinase regulation and inhibition by large scale structural comparison

Biochimica et Biophysica Acta - Proteins and Proteomics

Volumn 1804, Issue 3, 2010, Pages 429-432

  Eswaran, Jeyanthy ^a   Knapp, Stefan ^a,b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Atypical kinase; Kinase regulation; Protein kinase; Structure based drug design; X ray crystallography

Indexed keywords

IMATINIB; PROTEIN KINASE; PROTEIN KINASE INHIBITOR;

COMPARATIVE STUDY; ENZYME ACTIVE SITE; ENZYME INHIBITION; ENZYME REGULATION; HUMAN; LARGE SCALE PRODUCTION; MEDICAL TECHNOLOGY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DOMAIN; PROTEIN STRUCTURE; REVIEW; STRUCTURAL GENOMICS; STRUCTURE ANALYSIS;

ANIMALS; HUMANS; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; PROTEIN STRUCTURE, TERTIARY; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 75349102353     PISSN: 15709639     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbapap.2009.10.013     Document Type: Review

References (38)

1. Manning G., Plowman G.D., Hunter T., and Sudarsanam S. Evolution of protein kinase signaling from yeast to man. Trends Biochem. Sci. 27 (2002) 514-520
2. Capra M., Nuciforo P.G., Confalonieri S., Quarto M., Bianchi M., Nebuloni M., Boldorini R., Pallotti F., Viale G., Gishizky M.L., Draetta G.F., and Di Fiore P.P. Frequent alterations in the expression of serine/threonine kinases in human cancers. Cancer Res. 66 (2006) 8147-8154
3. Cohen P. Protein kinases-the major drug targets of the twenty-first century?. Nat. Rev. Drug Discov. 1 (2002) 309-315
4. Pawson T., and Scott J.D. Protein phosphorylation in signaling-50 years and counting. Trends Biochem. Sci. 30 (2005) 286-290
5. Fabian M.A., Biggs III W.H., Treiber D.K., Atteridge C.E., Azimioara M.D., Benedetti M.G., Carter T.A., Ciceri P., Edeen P.T., Floyd M., Ford J.M., Galvin M., Gerlach J.L.., Grotzfeld .R.M., Herrgard S., Insko D.E.., Insko M.A., Lai A.G., Lelias .J.M., Mehta S.A., Milanov .Z.V., Velasco .A.M., Wodicka L.M., Patel H.K., Zarrinkar P.P., and Lockhart D.J. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat. Biotechnol. 23 (2005) 329-336
6. Zhang J., Yang P.L., and Gray N.S. Targeting cancer with small molecule kinase inhibitors. Nat. Rev. Cancer 9 (2009) 28-39
7. Nolen B., Taylor S., and Ghosh G. Regulation of protein kinases; controlling activity through activation segment conformation. Mol. Cell 15 (2004) 661-675
8. Kornev A.P., Haste N.M., Taylor S.S., and Eyck L.F. Surface comparison of active and inactive protein kinases identifies a conserved activation mechanism. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 17783-17788
9. Johnson L.N., Noble M.E., and Owen D.J. Active and inactive protein kinases: structural basis for regulation. Cell 85 (1996) 149-158
10. Marsden B.D., and Knapp S. Doing more than just the structure-structural genomics in kinase drug discovery. Curr. Opin. Chem. Biol. 12 (2008) 40-45
11. Niedner R.H., Buzko O.V., Haste N.M., Taylor A., Gribskov M., and Taylor S.S. Protein kinase resource: an integrated environment for phosphorylation research. Proteins 63 (2006) 78-86
12. Oliver A.W., Paul A., Boxall K.J., Barrie S.E., Aherne G.W., Garrett M.D., Mittnacht S., and Pearl L.H. Trans-activation of the DNA-damage signalling protein kinase Chk2 by T-loop exchange. EMBO J. 25 (2006) 3179-3190
13. Pike A.C., Rellos P., Niesen F.H., Turnbull A., Oliver A.W., Parker S.A., Turk B.E., Pearl L.H., and Knapp S. Activation segment dimerization: a mechanism for kinase autophosphorylation of non-consensus sites. EMBO J. 27 (2008) 704-714
14. Oliver A.W., Knapp S., and Pearl L.H. Activation segment exchange: a common mechanism of kinase autophosphorylation?. Trends Biochem. Sci. 32 (2007) 351-356
15. Eswaran J., Lee W.H., Debreczeni J.E., Filippakopoulos P., Turnbull A., Fedorov O., Deacon S.W., Peterson J.R., and Knapp S. Crystal Structures of the p21-activated kinases PAK4, PAK5, and PAK6 reveal catalytic domain plasticity of active group II PAKs. Structure 15 (2007) 201-213
16. Filippakopoulos P., Kofler M., Hantschel O., Gish G.D., Grebien F., Salah E., Neudecker P., Kay L.E., Turk B.E., Superti-Furga G., Pawson T., and Knapp S. Structural coupling of SH2-kinase domains links Fes and Abl substrate recognition and kinase activation. Cell 134 (2008) 793-803
17. Eswaran J., Bernad A., Ligos J.M., Guinea B., Debreczeni J.E., Sobott F., Parker S.A., Najmanovich R., Turk B.E., and Knapp S. Structure of the human protein kinase MPSK1 reveals an atypical activation loop architecture. Structure 16 (2008) 115-124
18. Eswaran J., Patnaik D., Filippakopoulos P., Wang F., Stein R.L., Murray J.W., Higgins J.M., and Knapp S. Structure and functional characterization of the atypical human kinase haspin. Proc. Natl. Acad. Sci. U. S. A. 106 (2009) 20198-20203
19. Scheeff E.D., Eswaran J., Bunkoczi G., Knapp S., and Manning G. Structure of the pseudokinase VRK3 reveals a degraded catalytic site, a highly conserved kinase fold, and a putative regulatory binding site. Structure 17 (2009) 128-138
20. Schindler T., Bornmann W., Pellicena P., Miller W.T., Clarkson B., and Kuriyan J. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 289 (2000) 1938-1942
21. Liu Y., and Gray N.S. Rational design of inhibitors that bind to inactive kinase conformations. Nat. Chem. Biol. 2 (2006) 358-364
22. Adrian F.J., Ding Q., Sim T., Velentza A., Sloan C., Liu Y., Zhang G., Hur W., Ding S., Manley P., Mestan J., Fabbro D., and Gray N.S. Allosteric inhibitors of Bcr-abl-dependent cell proliferation. Nat. Chem. Biol. 2 (2006) 95-102
23. Engel M., Hindie V., Lopez-Garcia L.A., Stroba A., Schaeffer F., Adrian I., Imig J., Idrissova L., Nastainczyk W., Zeuzem S., Alzari P.M., Hartmann R.W., Piiper A., and Biondi R.M. Allosteric activation of the protein kinase PDK1 with low molecular weight compounds. The EMBO J. 25 (2006) 5469-5480
24. Debreczeni J.E., Bullock A.N., Atilla G.E., Williams D.S., Bregman H., Knapp S., and Meggers E. Ruthenium half-sandwich complexes bound to protein kinase Pim-1. Angew. Chem. Int. Ed. Engl. 45 (2006) 1580-1585
25. Atilla-Gokcumen G.E., Pagano N., Streu C., Maksimoska J., Filippakopoulos P., Knapp S., and Meggers E. Extremely tight binding of a ruthenium complex to glycogen synthase kinase 3. Chembiochem 9 (2008) 2933-2936
26. Tanaka H., Yoshimura Y., Nozaki M., Yomogida K., Tsuchida J., Tosaka Y., Habu T., Nakanishi T., Okada M., Nojima H., and Nishimune Y. Identification and characterization of a haploid germ cell-specific nuclear protein kinase (Haspin) in spermatid nuclei and its effects on somatic cells. J. Biol. Chem. 274 (1999) 17049-17057
27. Higgins J.M. Haspin-like proteins: a new family of evolutionarily conserved putative eukaryotic protein kinases. Protein Sci. 10 (2001) 1677-1684
28. Dai J., Sultan S., Taylor S.S., and Higgins J.M. The kinase haspin is required for mitotic histone H3 Thr 3 phosphorylation and normal metaphase chromosome alignment. Genes Dev. 19 (2005) 472-488
29. Dai J., and Higgins J.M. Haspin: a mitotic histone kinase required for metaphase chromosome alignment. Cell Cycle 4 (2005) 665-668
30. Dai J., Sullivan B.A., and Higgins J.M. Regulation of mitotic chromosome cohesion by Haspin and Aurora B. Dev. Cell 11 (2006) 741-750
31. Rosasco-Nitcher S.E., Lan W., Khorasanizadeh S., and Stukenberg P.T. Centromeric Aurora-B activation requires TD-60, microtubules, and substrate priming phosphorylation. Science 319 (2008) 469-472
32. Karaman M.W., Herrgard S., Treiber D.K., Gallant P., Atteridge C.E., Campbell B.T., Chan K.W., Ciceri P., Davis M.I., Edeen P.T., Faraoni R., Floyd M., Hunt J.P., Lockhart D.J., Milanov Z.V., Morrison M.J., Pallares G., Patel H.K., Pritchard S., Wodicka L.M., and Zarrinkar P.P. A quantitative analysis of kinase inhibitor selectivity. Nat. Biotechnol. 26 (2008) 127-132
33. Fedorov O., Marsden B., Pogacic V., Rellos P., Muller S., Bullock A.N., Schwaller J., Sundstrom M., and Knapp S. A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 20523-20528
34. Bain J., Plater L., Elliott M., Shpiro N., Hastie C.J., McLauchlan H., Klevernic I., Arthur J.S., Alessi D.R., and Cohen P. The selectivity of protein kinase inhibitors: a further update. Biochem. J. 408 (2007) 297-315
35. Fedorov O., Sundstrom M., Marsden B., and Knapp S. Insights for the development of specific kinase inhibitors by targeted structural genomics. Drug Discov. Today 12 (2007) 365-372
36. Scherr N., Honnappa S., Kunz G., Mueller P., Jayachandran R., Winkler F., Pieters J., and Steinmetz M.O. Structural basis for the specific inhibition of protein kinase G, a virulence factor of Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 12151-12156
37. Manhani K.K., Arcuri H.A., da Silveira N.J., Uchoa H.B., de Azevedo Jr. W.F., and Canduri F. Molecular models of protein kinase 6 from Plasmodium falciparum. J. Mol. Model 12 (2005) 42-48
38. Manning G., Whyte D.B., Martinez R., Hunter T., and Sudarsanam S. The protein kinase complement of the human genome. Science 298 (2002) 1912-1934